Journal of Internal Medicine Concepts & Practice >

2026 , Vol. 21 >Issue 01: 59 - 61

DOI: https://doi.org/10.16138/j.1673-6087.2026.01.08

Olverembatinib combined with inotuzumab ozogamicin in Philadelphia chromosome-positive acute lymphoblastic leukemia with multiple relapses: a case report

  • LIU Heng ,
  • XI Rui ,
  • PAN Yaozhu ,
  • WANG Zonghui ,
  • TIAN Hongjuan ,
  • MAO Dongfeng ,
  • WU Tao
Expand
  • Department of Hematology, the 940th Hospital of the Joint Logistic Support Force of the People’s Liberation Army of China, Lanzhou 730050, China

Received date: 2025-02-19

  Online published: 2026-04-08

Copyright

, 2025, Copyright reserved © 2025.
Fold

Abstract

Relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is difficult to treat, facing a poor prognosis and short overall survival. The usage of tyrosine kinase inhibitor (TKI) and immunotherapy has brought new hope for the treatment of R/R Ph+ ALL for patients. This paper retrospectively analyzed a patient with Ph+ ALL experiencing multiple relapses, who was treated with olverembatinib in combination with a reduced dose of inotuzumab ozogamicin. The patient achieved complete response (CR) and minimal residual disease (MRD) negativity upon reexamination two months later, attaining a near-complete molecular response (CMR). A review of relevant literature is included to provide clinical treatment experience.

Key words： olverembatinib; inotuzumab ozogamicin; relapsed/refractory; Philadelphia chromosome-positive acute lymphoblastic leukemia

Cite this article

LIU Heng , XI Rui , PAN Yaozhu , WANG Zonghui , TIAN Hongjuan , MAO Dongfeng , WU Tao . Olverembatinib combined with inotuzumab ozogamicin in Philadelphia chromosome-positive acute lymphoblastic leukemia with multiple relapses: a case report[J]. Journal of Internal Medicine Concepts & Practice, 2026 , 21(01) : 59 -61 . DOI: 10.16138/j.1673-6087.2026.01.08

References

[1] Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults[J]. Cancers (Basel), 2022, 14(7):1805.
[2] Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia[J]. Blood, 2015, 125(24):3711-3719.
[3] Jiang Q, Huang XJ, Chen Z, et al. Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase Ⅱ) trials[J]. Blood, 2020, 136(Suppl 1):50-51.
[4] Jiang Q, Li ZR, Hou Y, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation[J]. Blood, 2022, 140(Suppl 1):203-204.
[5] Jabbour E, Kantarjian HM, Koller PB, et al. Update of olverembatinib (HQP1351) overcoming ponatinib and/or asciminib resistance in patients (Pts) with heavily pretreated/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)[J]. Blood, 2023, 142(Suppl 1):1798
[6] Liang E, Min P, Xiong Y, et al. Olverembatinib (HQP1351) enhances antitumor effects of chemotherapy in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)[J]. Blood, 2023, 142(Suppl 1):5882
[7] Liu W, Wang C, Ouyang W, et al. Efficacy and safety of olverembatinib in adult BCR: : ABL1-positive ALL with T315I mutation or relapsed/refractory disease[J]. Br J Haematol, 2024, 205(6):2228-2233.
[8] Zhu Y, Huang J, Wang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Ann Hematol, 2024, 103(11):4643-4648.
[9] Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial[J]. J Hematol Oncol, 2022, 15(1):113.
[10] 中国临床肿瘤学会(CSCO)白血病专家委员会. 奥加伊妥珠单抗治疗急性淋巴细胞白血病临床应用指导原则(2023年版)[J]. 白血病·淋巴瘤, 2023, 32(8):449-456.
  Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Guideline principles for clinical application of inotuzumab ozogamicin in treatment of acute lymphoblastic leukemia (2023 version)[J]. J Leuk Lymphoma, 2023, 32(8):449-456.
[11] Short NJ, Jabbour E, Jain N, et al. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions[J]. J Hematol Oncol, 2024, 17(1):32.
[12] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(8):740-753.
[13] Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22[J]. Clin Cancer Res, 2021, 27(10):2742-2754.
[14] Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review[J]. Bone Marrow Transplant, 2018, 53(4):449-456.
Options
Outlines

/

〈 〉